The maiden human trial of a potential tuberculosis drug — the first in six years — has now commenced.
Known as TBA-354, the promising drug comes from a class of chemicals known to be effective against drug-sensitive and drug-resistant tuberculosis, deemed a major public health concern because it can derail progress made in TB treatment and care. The proportion of drug-resistant TB of the global TB numbers has stayed at the same level in recent years, but new cases rise by almost half a million annually, according to the World Health Organization.
Although considered a milestone, this news also hints at the sad state of research and development for TB drugs.
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Ma. Eliza VillarinoDevexElizaJV
Eliza is a veteran journalist focused on covering the most pressing issues and latest innovations in global health, humanitarian aid, sustainability, and development. A member of Mensa, Eliza has earned a master's degree in public affairs and bachelor's degree in political science from the University of the Philippines.
